Abstract
Since the global emergence of COVID-19, attention has increasingly turned toward its extrapulmonary manifestations, including involvement of the auditory and vestibular systems. Reports of tinnitus, vertigo, and sudden sensorineural hearing loss have prompted investigation into the susceptibility of the vestibulocochlear apparatus to viral, vascular, and immune-mediated injury. Parallel anecdotal and pharmacovigilance reports have described similar symptoms temporally associated with COVID-19 vaccination, raising questions regarding causality, coincidence, and mechanistic plausibility. This review synthesises current evidence regarding the etiology, pathophysiology, clinical presentation, and management of vestibulocochlear dysfunction in the context of both infection and immunisation, with emphasis on distinguishing established findings from areas of uncertainty.
Introduction
The vestibulocochlear system, comprising the cochlea and vestibular labyrinth, is highly metabolically active and uniquely vulnerable to ischemic and inflammatory insults. Viral infections have long been implicated in audiovestibular pathology, including sudden sensorineural hearing loss and vestibular neuritis. Against this background, the emergence of COVID-19 has provided a large-scale natural experiment in viral neurotropism and systemic inflammatory disease.
Early in the pandemic, attention focused primarily on respiratory compromise. However, subsequent clinical observation revealed a broad spectrum of neurological and otological symptoms. These included anosmia, dysgeusia, dizziness, tinnitus, and hearing loss, suggesting that SARS-CoV-2 may affect both peripheral sensory organs and central neural pathways.
Simultaneously, the rapid deployment of mRNA vaccines—most prominently the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine—introduced a distinct but related domain of inquiry: whether immune activation in the absence of infection could produce similar audiovestibular symptoms, and if so, through what mechanisms.
Etiological Considerations
Direct Viral Effects
SARS-CoV-2 gains cellular entry through ACE2 receptors, which are expressed in multiple tissues, including structures of the inner ear. Experimental work using human-derived inner ear organoids has demonstrated that hair cells and supporting cells may be susceptible to viral entry. This raises the possibility of direct cytopathic effects within the cochlea and vestibular apparatus.
Unlike many other organs, the inner ear lacks regenerative capacity. Damage to cochlear hair cells or spiral ganglion neurons is therefore often irreversible, making even transient insults clinically significant.
Microvascular and Thrombotic Injury
A defining feature of COVID-19 is endothelial dysfunction and a prothrombotic state. The cochlea is supplied by the labyrinthine artery, an end artery without collateral circulation. Even brief interruptions in perfusion may result in hypoxic injury.
Microthrombi, endothelial inflammation, and altered blood rheology have all been documented in COVID-19 and provide a plausible mechanism for sudden hearing loss or vestibular dysfunction. This vascular vulnerability distinguishes the inner ear from more resilient organ systems.
Immune-Mediated Mechanisms
The host immune response to SARS-CoV-2 is characterised in some cases by a dysregulated inflammatory cascade, including elevated cytokines such as IL-6 and TNF-α. These mediators may disrupt the delicate ionic balance of the endolymph and perilymph, impairing hair cell function.
Additionally, post-infectious autoimmune phenomena have been described across multiple organ systems. Molecular mimicry between viral antigens and host proteins may lead to immune-mediated injury of neural or sensory structures, including the vestibulocochlear nerve.
Central Nervous System Involvement
Beyond peripheral structures, SARS-CoV-2 has been associated with central nervous system abnormalities, including brainstem involvement. Given that vestibular processing depends on brainstem nuclei and cerebellar integration, central mechanisms may contribute to dizziness and imbalance, particularly in patients with prolonged or severe disease.
Clinical Phenotypes
Auditory Manifestations
Patients with COVID-19 have reported a range of auditory symptoms, most commonly tinnitus and sudden sensorineural hearing loss. Tinnitus is often described as high-pitched and persistent, though its severity varies widely.
Sudden hearing loss may present unilaterally or bilaterally and can occur during acute infection or in the post-acute phase. The incidence remains uncertain, in part due to underreporting and the difficulty of distinguishing causation from coincidence.
Vestibular Manifestations
Vertigo, dizziness, and imbalance are frequently reported symptoms. These may reflect peripheral vestibular dysfunction, central processing abnormalities, or systemic illness.
In some patients, symptoms resemble classical vestibular neuritis, while in others they are more consistent with nonspecific dizziness associated with systemic inflammation or deconditioning.
Temporal Patterns and Long-Term Sequelae
Audiovestibular symptoms may arise during acute infection, emerge during recovery, or persist as part of post-acute sequelae often termed “long COVID.” The persistence of symptoms suggests that, in at least some cases, structural or functional injury extends beyond transient inflammation.
Vaccination and Audiovestibular Symptoms
The widespread administration of mRNA vaccines has been accompanied by pharmacovigilance reports of tinnitus, vertigo, and, more rarely, hearing loss occurring after vaccination. These reports have prompted investigation into potential causal relationships.
It is essential to distinguish temporal association from causation. Large-scale epidemiological studies have generally not demonstrated an increased incidence of sudden hearing loss beyond baseline population rates following vaccination. Given the background incidence of these conditions, coincidental occurrence is expected in large populations.
Nevertheless, plausible biological mechanisms have been proposed. These include transient immune activation, cytokine release, and, in rare cases, autoimmune responses. Such mechanisms are not unique to COVID-19 vaccines and have been described following other immunisations.
Importantly, the balance of evidence indicates that the risk of audiovestibular complications is significantly greater following infection with SARS-CoV-2 than after vaccination. This distinction is critical in clinical counselling and public health communication.
Diagnostic Approach
Evaluation of suspected vestibulocochlear involvement should follow established clinical pathways. Audiometric testing remains the cornerstone of assessment for hearing loss, while vestibular testing—including videonystagmography and vestibular evoked myogenic potentials—can help localise dysfunction.
Magnetic resonance imaging may be indicated to exclude central pathology, particularly in atypical or severe presentations. A thorough history is essential to establish temporal relationships with infection or vaccination while avoiding overinterpretation of coincidence.
Therapeutic Strategies
Management of audiovestibular symptoms in this context largely mirrors standard care.
Sudden sensorineural hearing loss is typically treated with corticosteroids, administered either systemically or via intratympanic injection. Early treatment is associated with improved outcomes.
Vestibular symptoms may be managed with short-term vestibular suppressants, followed by vestibular rehabilitation therapy to promote central compensation. Tinnitus management includes sound therapy, cognitive behavioural approaches, and, where appropriate, hearing aids.
For patients with persistent symptoms following COVID-19, a multidisciplinary approach is often required, incorporating otolaryngology, neurology, and rehabilitation services.
Discussion
The evidence linking COVID-19 to vestibulocochlear dysfunction is biologically plausible and supported by a growing body of clinical and experimental data. However, the heterogeneity of reported symptoms and the lack of large, controlled studies limit definitive conclusions regarding incidence and prognosis.
In contrast, the association between COVID-19 vaccination and similar symptoms remains less clear. While case reports and surveillance data suggest that such events may occur, current evidence does not support a strong causal relationship at the population level.
This distinction underscores the importance of rigorous epidemiological analysis and cautious interpretation of individual reports. In an era of rapid information dissemination, the potential for misattribution is substantial.
Conclusion
Vestibulocochlear dysfunction represents a plausible and clinically relevant manifestation of COVID-19, arising through a combination of viral, vascular, and immune-mediated mechanisms. Recognition of these manifestations is important for timely diagnosis and management.
Although similar symptoms have been reported following COVID-19 vaccination, current evidence suggests that such occurrences are rare and not clearly causal, particularly when compared with the risks associated with infection itself.
Further research is required to clarify mechanisms, quantify risk, and optimise therapeutic strategies. Prospective studies with robust controls will be essential in resolving ongoing uncertainties and informing both clinical practice and public health policy.
References
- Cohen BE, Durstenfeld A, Roehm PC. Viral causes of hearing loss. Otolaryngol Clin North Am. 2014.
- Varga Z, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020.
- Mao L, et al. Neurologic manifestations of hospitalized COVID-19 patients. JAMA Neurol. 2020.
- Ellul MA, et al. Neurological associations of COVID-19. Lancet Neurol. 2020.
- Chen J, et al. ACE2 expression in human inner ear. Front Cell Neurosci. 2020.
- Jeong M, et al. Direct SARS-CoV-2 infection of human inner ear cells. Nat Commun. 2021.
- Gupta A, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020.
- Merchant SN, Durand ML, Adams JC. Sudden deafness: vascular causes. N Engl J Med. 2005.
- Koumpa FS, et al. Sudden hearing loss in COVID-19. BMJ Case Rep. 2020.
- Huang C, et al. Clinical features of COVID-19 patients. Lancet. 2020.
- Willison HJ, et al. Guillain-Barré syndrome. Lancet. 2016.
- Kremer S, et al. Brain MRI findings in COVID-19. Radiology. 2020.
- Almufarrij I, Munro KJ. Hearing loss and COVID-19: systematic review. Int J Audiol. 2021.
- Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021.
- Shimabukuro TT, et al. Vaccine safety monitoring (VAERS). JAMA. 2015.
- Formeister EJ, et al. SNHL after COVID vaccination. JAMA Otolaryngol. 2022.
- Yanir Y, et al. COVID vaccination and hearing loss. Clin Otolaryngol. 2022.
- Wichova H, et al. Tinnitus after COVID vaccination. Front Med. 2021.
- Chern A, et al. Otologic symptoms with COVID-19. Otol Neurotol. 2021.
- Chandrasekhar SS, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2019.
- Rauch SD. Clinical practice: idiopathic SNHL. N Engl J Med. 2008.
- Hall CD, et al. Vestibular rehabilitation guidelines. J Neurol Phys Ther. 2016.
- Fuller TE, et al. Cognitive behavioral therapy for tinnitus. Cochrane Database. 2020.